Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Week Phase IIIb/IV Single Arm Open Label Observational Study to Explore the Efficacy of Protease Inhibitors Given in Combination With Reverse Transcriptase Inhibitors to HIV-1 Infected Subjects With Protease Mutations Selected During Therapy With GW433908 Containing Antiretroviral Therapy

NCT00242840 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00242840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Week Phase IIIb/IV Single Arm Open Label Observational Study to Explore the Efficacy of Protease Inhibitors Given in Combination With Reverse Transcriptase Inhibitors to HIV-1 Infected Subjects With Protease Mutations Selected During Therapy With GW433908 Containing Antiretroviral Therapy
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2003
Completion date
January 31, 2006
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection, infection, human immunodeficiency virus i